{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:04:42Z","timestamp":1774940682141,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary Sj\u00f6gren\u2019s syndrome (pSS) is a chronic autoimmune disease characterized by lymphoplasmacytic infiltration of exocrine glands, leading to dry eyes and mouth. Renal involvement, particularly glomerulonephritis, occurs in approximately 5% of pSS patients. Membranous nephropathy (MN) is one of the less common forms of renal involvement in pSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 48-year-old female with a history of oral and ocular dryness for several years and bilateral symmetrical lower extremity edema for three months was admitted to our hospital. Laboratory findings revealed moderate anemia, hypoalbuminemia, and nephrotic-range proteinuria. Schirmer\u2019s test, tear break-up time, and lip biopsy confirmed the diagnosis of pSS. Renal biopsy demonstrated widespread mesangial hypercellularity and mesangial matrix expansion, thickening of the glomerular basement membrane(GBM) with prominent spikes, and subepithelial, intramembranous and mesangial electron-dense deposits under electron microscopy. Immunofluorescence showed diffuse fine granular deposits of IgG (predominantly IgG1 and IgG2). Based on these findings, secondary membranous nephropathy due to pSS was diagnosed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Treatment and outcome<\/jats:title>\n                    <jats:p>The patient was treated with prednisone (30 mg\/day) and two infusions of rituximab (1 g each, administered 2 weeks apart). After treatment, her 24-hour urinary protein level decreased from 8.5 g to 2.2 g. The dose of glucocorticoids was gradually tapered off. During follow-up, an additional 1 g of rituximab was administered six months later, resulting in a further reduction of proteinuria to 1.3 g\/24 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the effectiveness of rituximab in managing secondary membranous nephropathy associated with pSS. Further studies are needed to clarify the underlying mechanisms and optimize treatment strategies for this condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1682660","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:33:17Z","timestamp":1774935197000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case of rituximab for membranous nephropathy secondary to primary Sjogren\u2019s syndrome and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"XiaoJuan","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Nephrology, the First Affiliated Hospital of Chengdu Medical College","place":["Chengdu, China"]},{"name":"School of Clinical Medicine College, Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the First Affiliated Hospital of Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the First Affiliated Hospital of Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the First Affiliated Hospital of Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogren\u2019s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients","volume":"53","author":"Baldini","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B3","article-title":"Changes in glycosylation of immunoglobulins in primary Sj\u00f6gren\u2019s syndrome","volume":"149","author":"Basset","year":"1998","journal-title":"Ann Med Interne (Paris)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"Cmaj"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-043015-123313","article-title":"Mechanisms and new strategies for primary sj\u00f6gren\u2019s syndrome","volume":"68","author":"Mavragani","year":"2017","journal-title":"Annu Rev Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Med (Baltimore)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.12.2328","article-title":"Clinical and morphological features of kidney involvement in primary Sj\u00f6gren\u2019s syndrome","volume":"16","author":"Bossini","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00980209","article-title":"Renal involvement in primary Sj\u00f6gren\u2019s syndrome: a clinicopathologic study","volume":"4","author":"Maripuri","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2010.07.003","article-title":"Primary Sj\u00f6gren\u2019s syndrome with minimal change disease\u2013a case report","volume":"27","author":"Yang","year":"2011","journal-title":"Kaohsiung J Med Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"B11","article-title":"Efficacy of retreatment with rituximab in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"33","author":"Meiners","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.07.019","article-title":"Secondary renal amyloidosis due to long-standing tubulointerstitial nephritis in a patient with Sj\u00f6gren syndrome","volume":"46","author":"Ooms","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318801673","article-title":"Primary sj\u00f6gren\u2019s syndrome","volume":"27","author":"Bowman","year":"2018","journal-title":"Lupus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2008.08.009","article-title":"Relationship of Sj\u00f6gren\u2019s syndrome to other connective tissue and autoimmune disorders","volume":"34","author":"Theander","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23173","article-title":"Prevalence of primary sj\u00f6gren\u2019s syndrome in a US population-based cohort","volume":"69","author":"Maciel","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American college of rheumatology\/european league against rheumatism classification criteria for primary sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2017.0354","article-title":"The diagnosis and treatment of sj\u00f6gren\u2019s syndrome","volume":"114","author":"Stefanski","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.04.009","article-title":"ANCA-associated vasculitis in patients with primary Sj\u00f6gren\u2019s syndrome: detailed analysis of 7 new cases and systematic literature review","volume":"14","author":"Guellec","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40744-020-00264-x","article-title":"Renal disease in primary sj\u00f6gren\u2019s syndrome","volume":"8","author":"Aiyegbusi","year":"2021","journal-title":"Rheumatol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.38100","article-title":"Clinically significant renal involvement in primary Sj\u00f6gren\u2019s syndrome: clinical presentation and outcome","volume":"65","author":"Goules","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4103\/ijpm.ijpm_22_21","article-title":"Role of light and immunofluorescence microscopy to differentiate primary and secondary membranous nephropathy","volume":"65","author":"Basu","year":"2022","journal-title":"Indian J Pathol Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx366","article-title":"Anti-phospholipase A2 receptor antibodies in primary membranous nephropathy-10 key points","volume":"33","author":"McQuarrie","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1500130","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"372","author":"Meyer-Schwesinger","year":"2015","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg616","article-title":"Distribution of glomerular IgG subclass deposits in Malignancy-associated membranous nephropathy","volume":"19","author":"Ohtani","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv049","article-title":"Glomerular IgG subclasses in idiopathic and Malignancy-associated membranous nephropathy","volume":"8","author":"L\u00f6nnbro-Widgren","year":"2015","journal-title":"Clin Kidney J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12085","article-title":"Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO","volume":"23","author":"Verkman","year":"2013","journal-title":"Brain Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4226","article-title":"Aquaporins: important but elusive drug targets","volume":"13","author":"Verkman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult Scler"},{"key":"B39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.msard.2017.05.007","article-title":"Membranous nephropathy with Neuromyelitis optica spectrum disorder","volume":"15","author":"Li","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sj\u00f6gren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"Jama"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1682660\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:33:18Z","timestamp":1774935198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1682660\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1682660"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1682660","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1682660"}}